Recent Updates
Recently added Catalysts
SVRA Negative Sentiment Score: 25/100

Savara Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before November 7, 2025 to Discuss Your Rights – SVRA

Key Takeaway: Savara Inc. is being sued for securities law violations related to its pulmonary alveolar proteinosis treatment, MOLBREEVI. Allegations include the issuance of misleading statements regarding the treatment's development and expected FDA approval. The class period for affected shareholders is from March 4, 2024, to May 23, 2025, with a deadline for lead plaintiff registration on November 7, 2025. Investors are encouraged to participate in the class action to seek potential recovery for losses incurred due to the alleged omissions and misrepresentations.

Market Sentiment Analysis

CONCERNS & RISKS

  • Savara is facing a lawsuit alleging misleading statements about MOLBREEVI BLA.
  • Concerns about the FDA's approval likelihood for MOLBREEVI were not disclosed.
  • The company's potential need to raise additional capital has increased due to regulatory delays.

Full Press Release Details

NEW YORK, Oct. 16, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Savara Inc. (NASDAQ: SVRA).
Shareholders who purchased shares of SVRA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.
CLASS PERIOD: March 4, 2024 to May 23, 2025
ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (i) MOLBREEVI BLA, the treatment of pulmonary alveolar proteinosis, lacked sufficient information regarding MOLBREEVI’s chemistry, manufacturing, and/or controls; (ii) accordingly, FDA was unlikely to approve the MOLBREEVI BLA in its current form; (iii) foregoing made it unlikely that Savara would complete its submission of the MOLBREEVI BLA within the timeframe it had represented to investors; (iv) delay in MOLBREEVI’s regulatory approval increased the likelihood that the Company would need to raise additional capital; and (v) as a result, defendants’ public statements were materially false and misleading at all relevant times.
DEADLINE: November 7, 2025 Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/savara-inc-loss-submission-form/?id=172046&from=3
NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of SVRA during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is November 7, 2025. There is no cost or obligation to you to participate in this case.
WHY GROSS LAW FIRM? The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.
15 West 38th Street, 12th floor
Phone: (646) 453-8903

Tags

Frequently Asked Questions

What is the class period for Savara Inc. shareholders?

The class period for Savara Inc. shareholders is from March 4, 2024, to May 23, 2025.

What are the allegations against Savara Inc.?

Allegations include misleading statements regarding MOLBREEVI BLA's approval and information disclosure.

When is the deadline to seek lead plaintiff status?

The deadline to seek lead plaintiff status is November 7, 2025.

Is there a cost to participate in the class action?

There is no cost or obligation to participate in the class action.

What support do registered shareholders receive?

Registered shareholders receive updates through portfolio monitoring software.

Last updated: Oct 16, 2025